An Add-on Study to Evaluate the Efficacy and Safety of Xiyanping Injection in Pediatric Bronchitis Patients.

Last updated: December 4, 2017
Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Overall Status: Active - Recruiting

Phase

4

Condition

Bronchitis

Treatment

N/A

Clinical Study ID

NCT02937857
JXQF-XYP-1606
  • Ages 1-3
  • All Genders

Study Summary

This is a multicenter, randomized, open Label,add-on study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical diagnosis of pediatric bronchitis with hospital treatment needed

  • Males and female subjects

  • Age between 1 and 3 years old

  • With fever, cough, gasp and expectoration symptoms

  • Have wheeze and/ or mid-fine rales on one's lungs

  • White blood cell count < 12 x 109 / L, categorized priority to leukocyte

  • C-reactive protein≤8mg/L or normal Super C- reactive protein

  • Had experienced ≤48 h course before enrollment

  • Previous Wheezing episodes≤2

  • Written informed consent

Exclusion

Exclusion Criteria:

  • Participants with severe clinical symptoms, meet any of the following:

  • SaO2≤0.92;(2)Shock or disturbance of consciousness;(3) Significantly speed upbreathing , rapid pulse accompany with severe respiratory distress; or(4)Repeatedoccurrence of apnea or slow and irregular respiration;

  • Acute infectious disease such as measles, pertussis and influenza

  • Participants with bronchial asthma, bronchopneumonia and other respiratory diseases

  • Chronic lung diseases

  • Participants with complicated pyopneumothorax, airway obstruction, toxicencephalopathy, cardiac failure or respiratory failure

  • Participants with complicated severe underlying myocardial, liver, kidney, digestiveand hematopoietic system diseases

  • Severe malnutrition and history of immune deficiency which may seriously affect theself-limiting process of the course

  • Participants with epilepsy and other disturbances of central nervous system

  • Participants with congenital diseases and psychosis

  • use of any other antiviral drugs within the 2 weeks before enrollment

  • use of systemic hormone within the 2 weeks before enrollment

  • Participants had a history of allergic constitution and drug allergy; Allergenic toXiYanPing injection and Andrographolide

  • Participants participated in other clinical research in the last three months

  • Any condition which would make the subject, in the opinion of the investigator ordesignee, not suitable for the study for any reason

Study Design

Total Participants: 240
Study Start date:
August 01, 2016
Estimated Completion Date:
August 31, 2020

Study Description

This is an add-on study of efficacy and safety of intravenous injection of Xiyanping injection in subjects with pediatric bronchitis.

The purpose to determine the efficacy and safety of conventional treatment combined with or without Xiyanping injection in the treatment of pediatric bronchitis and to further evaluate the clinical value of Xiyanping injection in shortening the course of pediatric bronchitis

The study will enroll 240 Pediatric bronchitis volunteers, who will be randomized into 2 groups (1:1 ratio): volunteers from the first group will receive Routine treatment for pediatric bronchitis and Xiyanping injection; volunteers from the second group will receive Routine treatment for pediatric bronchitis. Xiyanping injection will be administration as intravenous injection of 0.2-0.4mL/kg/day once daily for 5 days concomitantly with Routine treatment for pediatric bronchitis

Connect with a study center

  • Guangzhou women and children health care center

    Guangzhou, Guangdong 510623
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.